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Abstract
Background. There is no agreement concerning dialyzate
glucose concentration in hemodialysis (HD) and 100 and
200 mg/dL (G100 and G200) are frequently used. G200
may result in diffusive glucose flux into the patient, with
consequent hyperglycemia and hyperinsulinism, and elec-
trolyte alterations, in particular potassium (K) and phos-
phorus (P). This trial compared metabolic effects of G100
versus G200.
Methods. Chronic HD patients participated in this random-
ized, single masked, controlled crossover trial (www.clinical-
trials.gov: #NCT00618033) consisting of two consecutive
3-week segments with G100 and G200, respectively. Intra-
dialytic serum glucose (SG) and insulin concentrations (SI)
were measured at 0, 30, 60, 120, 180, 240 min and immedi-
ately post-HD; P and K were measured at 0, 120, 180 min and
post-HD. Hypoglycemia was defined as an SG <70 mg/dL.
Mean SG and SI were computed as area under the curve
divided by treatment time.
Results. Fourteen diabetic and 15 non-diabetic subjects were
studied. SG was significantly higher with G200 as compared
to G100, both in diabetic {G200: 192.86 48.1 mg/dL; G100:
154.0 6 27.3 mg/dL; difference 38.8 [95% confidence inter-
val (CI): 21.2–56.4] mg/dL; P < 0.001} and non-diabetic
subjects [G200: 127.0 6 11.2 mg/dL; G100 106.5 6 10.8
mg/dL; difference 20.6 (95% CI: 15.3–25.9) mg/dL; P <
0.001]. SI was significantly higher with G200 in non-diabetic
subjects. Frequency of hypoglycemia, P and K serum levels,
interdialytic weight gain and adverse intradialytic events did
not differ significantly between G100 and G200.
Conclusion. G200 may exert unfavorable metabolic effects
in chronic HD patients, in particular hyperglycemia and
hyperinsulinism, the latter in non-diabetic subjects.
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Introduction
Hemodialysis (HD) fluid can be considered a temporary
extension of the patient’s extracellular fluid because of
the bi-directional transport processes when blood and dia-
lyzate are flowing through the dialyzer. Therefore, the
composition of the dialyzate is critical for the patient’s
electrolyte and metabolic homeostasis. Glucose is a main
dialyzate component, but there exists no general agree-
ment on the optimal level. In the 1960s, prior to the gen-
eral use of ultrafiltration in dialysis machines, the osmotic
forces induced by glucose were used for fluid removal and
dialyzate glucose concentrations of up to 1600 mg/dL
were used for this reason [1]. After ultrafiltration, which
has been firstly incorporated in a dialysis machine by the
Swedish scientist Nils Alwall, became a standard feature
of dialysis machines, high dialyzate glucose concentra-
tions lost importance. The addition of dialyzate glucose
remained standard of most dialysis providers, due to
concerns about hypoglycemia, but the optimal dialyzate
glucose concentration remained controversial. In the
USA, a dialyzate glucose concentration of 200 mg/dL
(11 mmol/L; G200) became standard until recently. In
Europe, the most frequently used glucose concentration
is 100 mg/dL (5.5 mmol/L; G100), whereas in some
countries glucose-free dialyzate (G0) is used, mainly
due to concerns about bacterial and fungal contamination
and economic considerations.
While several studies on G0 versus G200 and G100,
respectively [1–6], have been reported, data comparing
G100 and G200 are scarce [1, 6]. In particular, G100
and G200 have never been compared in a randomized
controlled trial (RCT).
Additionally, not much information has been reported
in recent years on glucose kinetics during HD. There is
evidence that glucose-containing dialyzate to some degree
prevents glucose losses from the patient and thus reduces
the risk of intradialytic hypoglycemia [2, 7, 8]. Diabetic
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HD patients treated with oral anti-diabetic agents or in-
sulin may be particularly prone to hypoglycemia because
eating during HD is discouraged due to adverse effects on
hemodynamic stability [9]. On the other hand, G200 may
result in overt intradialytic hyperglycemia and transient
hyperinsulinism [1, 2, 10].
Since insulin affects serum potassium levels by promot-
ing cellular potassium (K) uptake, hyperinsulinism may
thus reduce K removal by HD [10]. Hyperinsulinism may
also reduce phosphorus (P) removal during HD due to
increased cellular P uptake [11].
An additional theoretical consideration is the contribu-
tion of plasma glucose to plasma osmolality, although this
effect may be deemed negligible [5]. However, it cannot be
entirely excluded that intradialytic hyperglycemia may
result in increased thirst after dialysis and higher interdia-
lytic weight gains (IDWG); on the other hand, hyperglyce-
mia may promote fluid shifts from the intracellular to the
extracellular compartment and thus stabilizes blood pres-
sure during ultrafiltration.
In order to address the questions outlined above, we
embarked on an RCT of G100 and G200 in chronic HD
patients. The primary endpoint was mean intradialytic
serum glucose level; secondary endpoints included ad-
verse intradialytic events such as hypoglycemia or other
events requiring intervention as per the unit’s policy,
insulin levels, intradialytic glucose removal or gain,
intradialytic K and P concentrations, systolic blood
pressure (SBP), occurrence of cardiac arrhythmias and
IDWG.
Materials and methods
Patient selection
Maintenance HD patients dialyzed thrice weekly on a regular schedule at
two dialysis centers of the Renal Research Institute in New York City were
included in this single-masked crossover RCT (www.clinicaltrials.gov:
#NCT00618033). The study protocol was approved by the Institutional
Review Board of Beth Israel Medical Center, New York City, NY.
Patients signed informed consent prior to enrollment and the study was
conducted in full accordance with the Declaration of Helsinki.
Patients were enrolled according to the inclusion and exclusion criteria
(see below) regardless of gender, race and ethnicity. Inclusion criteria were
age18 years and HD vintage >30 days. Patients receiving HD other than
thrice weekly, those with a history of infection, antibiotic treatment or
hospitalization during the preceding month were excluded. The enrollment
target was 15 diabetic and 15 non-diabetic patients.
Diabetes mellitus was defined by either anti-diabetic therapy (oral
drugs or insulin) or a random blood glucose >200 mg/dL in the preceding
12 months.
Study design
The study comprised two randomized consecutive 3-week treatment
periods (nine HD treatments during each period) with G100 and
G200, respectively (Figure 1). Randomization of the treatment se-
quence was done at the facility level to avoid potential influence of
facility practice patterns. Study coordinators assured proper delivery of
the allocated treatment regimen. Throughout the entire study, patients
were masked to dialyzate glucose levels. Blinding of study coordina-
tors, technicians, nurses and physicians was not feasible for safety
reasons. In order to maintain the single-masked design, dialyzate was
administered via unlabled taps or jugs, depending on the facility. Dia-
lyzer type (Fresenius Optiflux F180NR), treatment time, blood and
dialyzate flow rates, target weights and medications remained
unchanged throughout the entire 6-week study period. No food was
provided during the study treatments and subjects were asked to refrain
from eating.
30 chronic hemodialysis 
patients enrolled
29 subjects randomized
on a facility level
1 subject excluded
(hospitalization)
8 diabetic subjects
13 non-diabetic subjects
6  diabetic subjects
2 non-diabetic subjects 
G200
(2 study treatments)
G100
(4 study treatments)
G 200
(2 study treatments)
G100
(4 study treatments) 
29 subjects
analyzed
6 diabetic subjects
2 non-diabetic subjects
8 diabetic subjects 
13 non-diabetic subjects
3 weeks
(9 HD treatments)
3 weeks
(9 HD treatments)
Fig. 1. Study flowchart.
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Measurements
In the units enrolled in the study, no previous experience with G100
existed and G200 was the standard dialyzate. Therefore, in order to address
concerns about the safety of G100, twice as many study treatments with
G100 were scheduled (four with G100 and two with G100). Study treat-
ments where blood samples were obtained were scheduled after long and
short interdialytic intervals in a 1:1 ratio.
Biochemistry
Serum glucose and insulin levels were measured at 0, 30, 60, 120, 180 min
and at the end of HD. Serum potassium and phosphorus were measured at
0, 120 min and at the end of HD. Glucose, phosphorus and potassium were
measured with standard methods using the Olympus AU5400 analyzer
(Olympus Diagnostics Systems, Center Valley, PA). Insulin was measured
with a chemiluminescent immunoassay implemented on the Advia
Centaur (Siemens Healthcare Diagnostics, Deerfield, IL). Hematocrit
was estimated from clinical routine measurements of mean erythrocyte
cell volume and red blood cell count. All measurements were performed
at a certified laboratory (Spectra Laboratories; Rockleigh, NJ). Data of
serum glucose are reported in conventional units (mg/dL), for conversion
to SI units (mmol/L), values have to be multiplied by 0.0555.
Glucose kinetics. Mean intradialytic serum glucose and insulin concen-
trations (SGmean; SImean) were calculated by the respective areas under the
curves divided by the duration of the treatment in minutes. The area under
the curve was calculated employing a third-order polynomial fit of
all measured intradialytic serum glucose and insulin concentrations,
respectively.
The glucose KoA of the dialyzer for the Fresenius Optiflux F180NR
was determined to be 0.749 L/min as per in vitro experiments using
aqueous solutions and heparinized bovine blood (D. Schneditz, unpub-
lished data). Glucose clearance was calculated as [12]:
K ¼ Qp:Qd:ð1 f Þ
Qp  Qd:f ; ð1Þ
where Qp is the effective plasma flow in liters per minute, Qd the dialyzate
flow in liters per minute and
f ¼ eKoA:

1
Qp
 1Qd

: ð2Þ
The plasma flow (Qp) in liters per minute was calculated as:
Qp ¼ Qb:

1  Hct
100

; ð3Þ
where Qb is the average blood flow during the treatment in liters per
minute and Hct the hematocrit as volume percentage of whole blood.
Per definition, glucose flux into the patient was considered as positive,
and out of the patient as negative.
The diffusive glucose mass transfer [MT (t)diffusive] in mg within the
time interval between two consecutive blood draws was calculated as
follows:
MTðtÞdiffusive ¼
h
K 

Gdialysate  SGðtÞaverage
i
 t; ð4Þ
where SG (t)average is the average plasma water glucose concentration in
mg/L (plasma concentration corrected for plasma void volume by the
factor 0.93) during the time interval of the duration t in minutes. A positive
glucose mass transfer corresponds to a diffuse glucose transfer from the
dialyzate to the patient. The total intradialytic diffusive glucose mass trans-
fer, MT (total)diffusive, in mg, was calculated as the sum of individual
glucose transfers over all time intervals.
The convective glucose mass transfer in mg during the time interval
between two consecutive blood draws was calculated as follows:
MTðtÞconvective ¼ 

UFV

t
  SGðtÞaverage

; ð5Þ
where UFV is the ultrafiltration volume removed, in liters, during the time
interval t, in minutes. The total convective glucose loss, MT (total)convective
in milligram, was calculated as the sum of the individual convective glu-
cose losses over all time intervals.
The total intradialytic extracorporal glucose mass transfer was calcu-
lated as the sum of diffusive and convective mass transfer:
MT ¼ MTðtotalÞdiffusive þMTðtotalÞconvective: ð6Þ
Insulin kinetics. Dialyzer insulin clearance was estimated from insulin’s
molecular weight: a linear equation was generated (least squares regression)
describing solute clearance as a function of the logarithm of the solute’s
molecular weight. The data used to fit this regression were the in vitro
clearances of urea, sodium, creatinine, phosphorus, vitamin B12 and lyso-
zyme at a solute diffusion volume flow rate of 0.3 L/min and a dialyzate
flow rate of 0.5 L/min (provided by the dialyzer manufacturer) and the
logarithms of those solutes’ molecular weights. Insulin clearance was esti-
mated using this equation, based on its molecular weight. The insulin mass
transfer area coefficient (KoA) was then calculated according to Michaels
[12] after correction for plasma void volume using the factor 0.93.
Other measures. Intradialytic SBP was recorded at time points 0, 30, 60,
120, 180 min and end of HD by an oscillometric method.
Holter recordings were performed after the long interdialytic interval,
once each with HD100 and HD200, commencing about 10 min before HD.
Electrocardiograms (ECGs) were continuously recorded at a sampling rate
of 250 Hz with a three-lead Holter device (clickholter, Cardioline; Health-
Frontier Inc., Branchburg, NJ) for 24 h. The Holter recordings were ana-
lyzed by an ECG analyst blinded to the dialyzate.
In diabetic subjects, hypoglycemia was defined as a serum glucose <70
mg/dL [13].
Intradialytic adverse events and appropriate interventions (such as
administration of saline in the event of intradialytic hypotension) were
defined and treated as per the unit’s policy.
IDWG was defined as the difference between pre-HD weight and the
preceding post-HD weight.
Statistical analyses
Normality of data was assessed by the Kolmogorov–Smirnoff test.
Student’s t-test was employed to compare demographics, treatment char-
acteristics, SBP, ultrafiltration volume, IDWG, mean glucose and insulin
concentrations, diffusive and convective glucose mass transfer during HD
using G100 and G200. Z-test was used to test the statistical significance of
insulin and glucose transfer. Mann–Whitney U-test was used to compare
the difference of occurrence of cardiac arrhythmias between G100 and
G200. McNemar change test was employed to compare the incidence of
hypoglycemia and adverse intradialytic events with G100 and G200 on a
patient level. In two sensitivity analyses, (i) diabetic subjects not on anti-
diabetic medication or insulin and (ii) treatments where food was ingested
in the very beginning of the HD treatment were excluded. A P-value <0.05
was considered statistically significant for all tests. All statistical analyses
were done with SPSS 17.0 (SPSS Inc., Chicago, IL).
Results
Thirty patients (15 diabetic and 15 non-diabetic subjects)
were enrolled during the period from April to June 2008.
One subject had to be withdrawn prior to randomization
due to hospitalization (Figure 1). Twenty-nine subjects
underwent 551 study treatments in total, 286 with G200
and 264 with G100, respectively. Demographics are shown
in Table 1 and dialysis treatment parameters in Table 2.
Biochemistry
Serum glucose (SG) and insulin (SI). SGmean was signifi-
cantly higher with G200 (n ¼ 56) compared to G100 (n ¼
104) (Table 3) in diabetic (G100: 154.0  27.3 mg/dL;
G200: 192.8  48.1 mg/dL; P < 0.001) and non-diabetic
(G100: 106.5  10.8 mg/dL; G200: 127.0  16.8 mg/dL;
P < 0.001) subjects. At the beginning of HD, SG did not
differ between G100 and G200 in either group (Table 2).
By 30 min, both diabetic and non-diabetic subjects showed
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Table 3. Diffusive and convective (MTdiffusive and MTconvective), total mass transfer and mean serum glucose (SGmean) during HD using 100 (G100) and
200 (G200) mg/dL dialyzate glucose concentrations (G100: 104 treatments; G200: 56 treatments)a
Diabetic subjects Non-diabetic subjects
SGmean (mg/dL) MTdiffusive (g) MTconvective (g)
Total mass
transfer (g) SGmean (mg/dL) MTdiffusive (g) MTconvective (g)
Total mass
transfer (g)
G100 154.0 6 27.3 30.1 6 14.7 4.7 6 1.7 34.8 6 16.0 106.5 6 10.8 5.0 6 5.9 2.9 6 0.8 7.9 6 6.2
G200 192.8 6 48.1 11.6 6 25.8 4.9 6 1.8 1.4 6 27.1 127.0 6 11.2 28.5 6 7.0 3.8 6 0.8 24.8 6 7.2
Difference
G100 – G200
(95% CI)
38.8 (56.4
to 21.2)*
25.2 (32.5
to 17.9)*
1.9 (1.0
to 2.9)*
23.2 (31.2
to 15.2)*
20.6 (25.9
to 15.3)*
33.5 (37.6
to 28.2)*
0.8 (0.2
to 1.5)*
32.7 (37.2
to 28.2)*
aData of serum glucose are reported in conventional units (mg/dL), for conversion to SI units (mmol/L) values have to be multiplied by 0.0555.
*P < 0.05.
Table 2. HD treatment parametersa
Diabetic subjects (n ¼ 14) Non-diabetic subjects (n ¼ 15)
G100 G200 G100 G200
Treatments (number) 126 138 138 148
Treatment time (min) 207 6 31 210 6 33 213 6 25 214 6 21
Dialyzate Na1 concentration (mmol/L) 138 138 138 138
Dialyzate K1 concentration (mmol/L) (2/3) 13/1 13/1 14/1 14/1
Dialyzate Ca11 concentration (mmol/L) (1.125/1.5) 14/0 14/0 14/1 14/1
Dialyzate temperature (C) 37 37 37 37
Blood flow (mL/min)b 401 6 13 408 6 28 396 6 32 399 6 21
Hematocrit (%)b 36 6 4 35 6 3 35 6 3 36 6 4
Plasma flow (mL/min)b 259 6 21 265 6 24 257 6 23 256 6 20
Urea kinetic volume (L) 34 6 6 34 6 6 36 6 7 36 6 7
IDWG (kg) 2.3 6 0.9 2.3 6 1.0 2.3 6 1.3 2.4 6 1.1
Weight change during HD (pre-HD weight – post-HD weight) (kg) 2.3 6 1.0 2.3 6 1.2 2.4 6 0.8 2.9 6 2.1
Intradialytic saline administration (count) 21 24 25 26
Reasons for saline administration
(hypotension/cramps/access/reason not specified)
6/7/2/6 6/4/4/10 5/1/7/9 7/5/5/8
Pre-HD serum glucose (mg/dL)b 176.9 6 49.1 189.7 6 114.0 109.6 6 17.3 112.7 6 24.7
Pre-HD serum insulin (mU/L)b 45.6 6 24.6 44.5 6 28.4 35.4 6 27.2 41.3 6 31.0
aData reported as mean6 SD. Data of serum glucose are reported in conventional units (mg/dL), for conversion to SI units (mmol/L) values have to be
multiplied by 0.0555.
bValues marked were only assessed on days where blood draws where conducted (G100: 104 treatments; G200: 56 treatments). No statistically
significant differences between G100 and G200 have been found.
Table 1. Demographics of study cohorta
All subjects Diabetic subjects Non-diabetic subjects
n 29 14 15
Age (years) 54 6 13 59 6 12 49 6 11
Gender (m/f) 15/14 6/8 9/6
Race (black/non-black) 16/13 8/6 6/9
Dialysis vintage (years) 5 6 4 3 6 3 6 6 5
Height (cm) 167 6 10 164 6 11 170 6 10
Post-HD weight (kg) 81 6 19 78 6 19 84 6 20
Post-HD body mass index (kg/m2) 28 6 7 28 6 6 28 6 7
Beta blocker (b1-selective/a1-b1-selective) 6/8 3/5 3/3
Anti-hypertensive drugs (ACE inhibitors/ARB/CCB) 4/4/13 2/4/8 2/0/5
Type of diabetes (Type 1/Type 2) 1/13 1/13 n.a.
Diabetes-related medication (insulin/oral anti-diabetic drugs) 9/3 9/3 n.a.
aData reported as mean 6 SD. No statistically significant differences between G100 and G200 have been found. ACE, angiotensin-converting enzyme;
ARB, angiotensin receptor blocker; CCB, calcium channel blocker; n.a., not applicable.
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significantly higher plasma glucose concentrations during
dialyses using G200. This difference was significant
throughout the whole treatment in both groups (Figure 2).
SImean was significantly higher in non-diabetic subjects
during G200 treatments (G100: 33.4  12.6 mU/L;
G200: 50.5 40.3 mU/L; P < 0.05). Non-diabetic subjects
showed significantly higher mean insulin levels at 30 min.
In contrast, diabetic subjects did not show significant dif-
ferences of SImean between G100 and G200, a finding
which was consistent throughout the entire treatment
(Figure 3).
In subjects with diabetes, hypoglycemia was observed
none of the treatments with G200 and in four treatments
with G100 (P ¼ 0.13).
Glucose mass transfer. Diabetic subjects gained on aver-
age 1.4 27.1 g of glucose during HD using G200 and lost
34.8  16.0 g of glucose when using G100. In contrast,
non-diabetic subjects gained 24.8  7.2 g using G200 and
lost 7.9  6.2 g using G100 (Table 3).
Insulin mass transfer. Based on information provided by
the manufacturer, the KoA of insulin was estimated to be
0.165 L/min in average, which translates into an insulin
clearance between 0.103 and 0.122 L/min, depending on
the individual blood and dialyzate flow rates. The estimated
insulin clearances allowed us to calculate the intradialytic
insulin removal in the 14 diabetic (G200: 0.9  0.4 IU;
G100: 0.9  0.4 IU per treatment, n.s.) and 15 non-diabetic
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Fig. 2. Serum glucose concentrations during HD using dialyzate glucose concentrations of 100 mg/dL (G100, depicted as circles connected with a full
line) and 200 mg/dL (G200, depicted as rhomboids connected with a dashed line) in (a) diabetic (n ¼ 14, on the left) and (b) non-diabetic subjects (n ¼
15, on the right). Data of serum glucose are reported in conventional units (mg/dL), for conversion to SI units (mmol/L) values have to be multiplied by
0.0555. *P < 0.05.
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subjects (G200: 1.5  0.9 IU; G100: 1.0  0.5 IU per
treatment, n.s.).
Potassium/phosphorus. Mean serum potassium levels
did not show substantial differences between G100 and
G200 at any time point (Table 4). In diabetic subjects,
P concentration at the end of HD was slightly lower with
G100 (G100: 1.9  0.4 mg/dL; G200: 2.1  0.3 mg/dL;
P < 0.05) (Table 5). In non-diabetic subjects, early decline
in P was more pronounced with G100.
IDWG, SBP, Holter recordings and adverse events
SBP (Figure 4; Table 6) and intradialytic adverse events did
not differ significantly between G100 and G200 (Table 2).
IDWG was not affected by dialyzate glucose. Cardiac ar-
rhythmias (supraventricular and ventricular tachycardia
and ventricular extrasystolic beats) did not differ between
G100 and G200.
Sensitivity analysis
Exclusion of (i) patients not receiving insulin and/or anti-
diabetic medication (n ¼ 2) and (ii) treatments where food
was ingested in the very beginning of the HD treatment
(G100: 23 treatments and G200: 14 treatments) did not alter
the results materially (data not shown).
Discussion
To the best of our knowledge, this is the first RCT
to compare the metabolic effects of G200 and G100
during dialysis. The main findings are significantly lower
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Fig. 3. Serum insulin concentrations during HD using dialyzate glucose concentrations of 100 mg/dL (G100, depicted as circles connected with a full
line) and 200 mg/dL (G200, depicted as rhomboids connected with a dashed line) in (a) diabetic (n ¼ 14, on the left) and (b) non-diabetic subjects (n ¼
15, on the right). *P < 0.05.
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glucose shifts from the dialyzate to the subject’s blood
with the use of G100 and correspondingly lower SG
and SI levels without effects on hemodynamic stability
and without the occurrence of symptomatic hypoglycemic
events.
The interpretation of the intradialytic glucose and insulin
levels has to consider the insulin removal via the dialyzer
[14, 15] and also a large variability of SG and SI levels
between the studied subjects. It has been proposed recently
that insulin removal is mainly due to adsorption and not
due to dialysis [16]. If this is correct, our insulin removal
estimate may be to some extent inaccurate. Notwithstand-
ing these considerations, insulin removal by the dialyzer is
likely to result in an increased insulin secretion in non-
diabetic subjects. The basal insulin secretion rate ranges
from 15 to 18 mU/min in healthy subjects [17], which
translates to ~3.5–4.5 IU over the course of an HD treat-
ment. Insulin secretion can be increased up to a total of 1.4
IU/12.5 g of ingested glucose in healthy subjects [17]. In-
sulin removal via the dialyzer in tandem with failure to
adequately increase insulin secretion despite the presence
of hyperglycemia may contribute to the steady intradialytic
decline of insulin levels observed in diabetic subjects
(Figures 2 and 3). The absence of significant differences
in insulin concentrations between G100 and G200, despite
significant differences in glucose concentrations, may
indicate impaired insulin secretion. To what extent the ure-
mic milieu affects insulin secretion and contributes to de-
fective beta cell function, as suggested by several authors
[18, 19], warrants future studies.
Average serum glucose levels over the course of HD
were significantly higher with G200 as compared to
G100 (Figure 2). This is readily explained by a larger glu-
cose gradient between dialyzate and blood, which results in
a diffusive flux of glucose into the patient (Table 3). In
diabetic subjects, this resulted in a glucose mass transfer
in the range of 159 g to 22 g (636 to 88 calories) with
G200 and 158 to 4 g (632 to 16 calories) with
G100. In non-diabetic subjects, glucose mass transfer
ranged from 1 to 37 g (4 to 148 calories) with G200 and
14 to 10 g (56 to 40 calories) with G100. Burmeister
reported an average glucose removal of 16.7 g (66.8 calo-
ries)] per hour with G0 and 5.2 g (20.8 calories) per hour
with G90 in diabetic and non-diabetic patients. Ward et al.
reported a total intradialytic glucose gain with G200 be-
tween 18.2 and 20.6 g (72.8 to 82.4 calories) in diabetic and
non-diabetic patients. In contrast, total glucose removal
with G0 was between 27.7 and 29.3 g (110.8 to 117.2
calories) in diabetic and non-diabetic patients [2, 10]. These
results show the importance of considering adequate
dialyzate glucose concentration to avoid either glucose
loading or excessive losses. In addition, it is important to
note that this amount of glucose enters the circulation intra-
venously and may not adequately induce physiological
reactions, such as insulin section stimulated by gastric
and/or duodenal hormones (e.g. GLP-1), as compared to
oral ingestion. As a consequence of blunted insulin secre-
tion, glucose remains at higher concentrations for a longer
time in the circulation, which may result in more pro-
nounced adverse effects.
Table 4. Serum potassium (K1) concentrations in diabetic and non-diabetic patients at the beginning, after 120 min and at the end the end of HD and the
temporal changes during the course of HD treatments using 100 (G100) and 200 mg/dL (G200) dialyzate glucose (G100: 104 treatments; G200: 56
treatments)a
Pre-HD K1 K1 120 min K
1
end HD
Diabetic subjects
G100 4.8 6 0.4 3.6 6 0.5 3.5 6 0.2
G200 5.2 6 0.9 3.7 6 0.4 3.5 6 0.2
Difference G100 – G200 (95% CI) 0.4 (1.0 to 0.2) 0.1 (0.3 to 0.1) 0 (0.1 to 0.2)
Non-diabetic subjects
G100 4.9 6 0.5 3.5 6 0.5 3.6 6 0.3
G200 4.8 6 0.4 3.5 6 0.4 3.3 6 0.4
Difference G100 – G200 (95% CI) 0.1 (0.1 to 0.3) 0 (0.2 to 0.2) 0.3 (0.1 to 0.7)
aNo statistically significant differences between G100 and G200 have been found.
Table 5. Serum phosphorus (P) concentrations in diabetic and non-diabetic patients at the beginning, after 120 min and at the end and the temporal
changes during the course of HD treatments using 100 (G100) and 200 mg/dL (G200) dialyzate glucose concentrations (G100: 104 treatments; G200: 56
treatments)
Pre-HD P P120 min Pend HD
Diabetic subjects
G100 4.9 6 0.9 2.3 6 0.3 1.9 6 0.4
G200 5.2 6 0.8 2.4 6 0.3 2.1 6 0.3
Difference G100 – G200 (95% CI) 0.3 (0.9 to 0.3) 0.1 (0.3 to 0) 0.2 (0.3 to 0.1)*
Non-diabetic subjects
G100 5.9 6 0.8 2.6 6 0.6 2.5 6 0.4
G200 5.5 6 1.2 2.6 6 0.4 2.2 6 0.4
Difference G100 – G200 (95% CI) 0.4 (0.0 to 0.7) 0 (0.2 to 0.2) 0.4 (0.0 to 0.7)
*P < 0.05.
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Fig. 4. SBP during HD using dialyzate glucose concentrations of 100 mg/dL (G100, depicted as rhomboids connected with a full line) and 200 mg/dL
(G200, depicted as circles connected with a dashed line) in (a) diabetic (n ¼ 14, on the left side) and (b) non-diabetic subjects (n ¼ 15, on the right side).
*P < 0.05.
Table 6. SBP in diabetic and non-diabetic subjects during the course of HD treatments where blood samples were obtained, using dialyzate with 100
(G100) and 200 mg/dL (G200) of glucose (G100: 104 treatments; G200: 56 treatments)a
SBPpre-HD SBP30 min SBP60 min SBP120 min SBP180 min SBPend HD
Diabetic subjects
G100 SBP (t) 146 6 17 137 6 23 128 6 22 124 6 17 121 6 19 124 6 19
G200 SBP (t) 144 6 16 137 6 13 134 6 20 124 6 15 125 6 17 128 6 16
Difference G100  G200 (95% CI) 2 (6 to 10) 0 (8 to 9) 6 (17 to 5) 0 (9 to 8) 3 (11 to 5) 4 (13 to 5)
Non-diabetic subjects
G100 SBP (t) 138 6 15 135 6 16 133 6 15 126 6 19 127 6 14 132 6 15
G200 SBP (t) 140 6 14 135 6 17 135 6 18 130 6 12 129 6 15 127 6 15
Difference G100  G200 (95% CI) 2 (7 to 3) 0 (7 to 7) 1 (7 to 5) 3 (11 to 5) 10 (31 to 12) 8 (2 to 19)
aNo statistically significant differences between G100 and G200 have been found.
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Malnutrition is prevalent in a high percentage of chronic
HD patients and it has been suggested that dialyzate glu-
cose could serve as a means to improve nutritional status
[20]. It is conceivable that highly malnourished patients
may have potential benefit from the intradialytic glucose
influx with G200. Nevertheless, given the discouraging
results with hypercaloric intradialytic parenteral nutrition
[21], we deem it unlikely that G200 would result in
improved nutritional status and result in better outcomes.
Glucose mass transfer was estimated based on glucose
KoA determined for the specific polysulfone high-flux
dialyzer used in our study (Fresenius Optiflux F180NR).
For the calculation of glucose mass transfer, the glucose
levels between two consecutive time points were interpo-
lated by a linear function to calculate the mean glucose
gradient in a given time interval. The glucose concentration
between two measurements may not necessarily follow a
linear function. For a more detailed understanding of intra-
dialytic glucose and insulin kinetics, future studies may
employ shorter sampling intervals and may also be vali-
dated by estimations by kinetic modeling by direct dialysis
quantification (DDQ).
Post-dialytic potassium and phosphorus concentrations
did not differ substantially between G100 and G200, irre-
spective of diabetes status (Table 4 and Table 5). This may
be due to transient hyperinsulinism, which is known to
cause shifts of potassium and phosphorus in the intracellu-
lar compartment. To refute the notion that G200 may result
in reduced dialytic K and P removal future studies, adjust-
ing concentrations and the resulting gradients for plasma
void volume are needed. The intradialytic change in phos-
phorus levels was slightly lower in diabetic subjects with
G200, a finding of potential clinical significance requiring
further research and validation by DDQ.
Hypoglycemia has been a major concern with the use
of G100 instead of G200. Our study showed no signifi-
cantly different frequency of hypoglycemia with G100.
All hypoglycemic episodes were asymptomatic.
Differences in activation of the autonomic nervous sys-
tem during dialysis using G100 and G200 have been re-
cently reported [22]. This and theoretical considerations of
differences in osmolality raised concern for more intradia-
lytic events, in particular hypotension, with the use of lower
dialysate glucose concentrations. Our clinical results indi-
cate no difference in SBP, intradialytic adverse events or
saline use between G100 and G200 (Figure 4; Table 2 and
Table 6). No difference in the occurrence of cardiac ar-
rhythmias, which may have been caused by temporary
shifts of K between the intra- and extracellular compart-
ment, was found between both concentrations.
Hyperinsulinism as a result of G200 deserves consid-
eration because it may induce pro-inflammatory
cytokines and promote insulin resistance [e.g. via ras-
related-associated-with-diabetes-gene (RRAD), serum/
glucocorticoid-regulated kinase (SGK)]. Of note, hyper-
insulinism as short as 4 h has been shown to induce these
effects [23]. Other adverse effects of hyperglycemia
are its associated cardiovascular risks [24–26] and
pro-thrombotic [27, 28] and pro-inflammatory effects
[29, 30]. It may be noted at this point that other studies
have shown anti-inflammatory effects of insulin infu-
sions in hospital settings [31, 32] and during the course
of HD treatments [33]. However, this requires additional
research and had not been a subject of this investigation.
Limitations are the small sample size, which is of partic-
ular importance in the analysis of the few hypoglycemic
events, and the short study duration. Furthermore, the exact
doses and the timing of the intake of insulin and anti-
diabetic medication are unknown. However, since patients
were blinded to the dialyzate glucose concentration, it is
unlikely that doses of insulin and oral anti-diabetic drugs
were changed systematically. In addition, sensitivity anal-
ysis showed no influence of anti-diabetic therapy on the
results. It also needs to be noted that this study was not
designed and not powered to test for differences in hypo-
glycemia between G100 and G200, and future adequately
powered studies also investigating hard outcomes such as
hospitalization and survival are warranted, including
adjustments of anti-diabetic therapy with lower dialyzate
glucose levels, both in patients with oral anti-diabetic drugs
and insulin therapy. Trials studying hard end points could
also help to answer the important question of the optimal
dialyzate glucose concentration.
Measurement of triglycerides was not available in this
study and may be considered in future projects. It may also
be noted that it was not captured when the last meal prior to
HD was ingested. However, with regard to subjects being
blinded to the dialyzate they received, this is unlikely to be
of significance when comparing both periods. Furthermore,
sensitivity analysis excluding treatments where patients in-
gested food at the very beginning of dialysis also did not alter
the results of the study. Finally, the mean age of the study
population (54  13 years) was substantially lower than that
of the general US HD population (61.3  15 years) [34]; in
addition, study subjects were only recruited in two different
urban dialysis clinics in New York City, all of which may
potentially affect the external validity of this study. However,
these limitations are in part outweighed by the randomized
crossover design and the paired analysis. In particular, the
paired fashioned analysis and the comparison of two consec-
utive mid-term study periods without intra-individual varia-
bility by virtually unchanged dialysis and medications
prescriptions are major strengths of this study.
To our knowledge, this is the first study comparing the
metabolic effects of G200 versus G100 in a randomized,
prospective crossover trial. In this short-term study, HD
with G100 reveals a more favorable metabolic profile both
in patients with and without diabetes mellitus as compared
to G200. Adverse events (intradialytic hypotension and
hypoglycemia) did not differ between the two dialyzate
glucose concentrations. Larger trials are necessary to fur-
ther address the potential association of hypoglycemia and
G100 and to investigate the effects on hard outcomes such
as hospitalizations and survival.
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